Imperial College London
Portrait Picture

Professor M Francesca Cordeiro

Faculty of Medicine, Department of Surgery & Cancer

Chair in Ophthalmology (Clinical)
 
 
 
//

Contact

 

m.cordeiro

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cordeiro:2022:10.1016/j.preteyeres.2021.100976,
author = {Cordeiro, MF and Hill, D and Patel, R and Corazza, P and Maddison, J and Younis, S},
doi = {10.1016/j.preteyeres.2021.100976},
journal = {Progress in Retinal and Eye Research},
title = {Detecting retinal cell stress and apoptosis with DARC: progression from lab to clinic},
url = {http://dx.doi.org/10.1016/j.preteyeres.2021.100976},
volume = {86},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - DARC (Detection of Apoptosing Retinal Cells) is a retinal imaging technology that has been developed within the last 2 decades from basic laboratory science to Phase 2 clinical trials. It uses ANX776 (fluorescently labelled Annexin A5) to identify stressed and apoptotic cells in the living eye. During its development, DARC has undergone biochemistry optimisation, scale-up and GMP manufacture and extensive preclinical evaluation. Initially tested in preclinical glaucoma and optic neuropathy models, it has also been investigated in AMD, Alzheimer's, Parkinson's and Diabetic models, and used to assess efficacy of therapies. Progression to clinical trials has not been speedy. Intravenous ANX776 has to date been found to be safe and well-tolerated in 129 patients, including 16 from Phase 1 and 113 from Phase 2. Results on glaucoma and AMD patients have been recently published, and suggest DARC with an AI-aided algorithm can be used to predict disease activity. New analyses of DARC in GA (Geographic Atrophy) prediction are reported here. Although further studies are needed to validate these findings, it appears there is potential for the technology to be used as a biomarker. Much larger clinical studies will be needed before it can be considered as a diagnostic, although the relatively non-invasive nature of the nasal as opposed to intravenous administration would widen its acceptability in the future as a screening tool.This review describes DARC development and its progression into Phase 2 clinical trials from lab-based research. It discusses hypotheses, potential challenges, and regulatory hurdles in translating technology.
AU  - Cordeiro,MF
AU  - Hill,D
AU  - Patel,R
AU  - Corazza,P
AU  - Maddison,J
AU  - Younis,S
DO  - 10.1016/j.preteyeres.2021.100976
PY  - 2022///
SN  - 1350-9462
TI  - Detecting retinal cell stress and apoptosis with DARC: progression from lab to clinic
T2  - Progress in Retinal and Eye Research
UR  - http://dx.doi.org/10.1016/j.preteyeres.2021.100976
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000744075200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://www.sciencedirect.com/science/article/pii/S1350946221000379
UR  - http://hdl.handle.net/10044/1/104394
VL  - 86
ER  -
Download